Consolidated Standards of Reporting Trials diagram for participant selection. Progression includes relapsed/refractory CLL and histologic transformation. Patients who died or received subsequent treatment without documented progression were excluded. LOT1, first-line therapy; LOT ≥2, second or further lines of therapy.